The G20210A prothrombin-gene mutation and the plasminogen activator inhibitor (PAI-1) 5G/5G genotype are associated with early onset of severe preeclampsia

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 4, 2005, Pages 686-691

  Gerhardt, A ^a   Goecke, T W ^b   Beckmann, M W ^b   Wagner, K J ^a   Tutschek, B ^a   Willers, R ^a   Bender, H G ^a   Scharf, R E ^a   Zotz, R B ^a,c  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

G20210A prothrombin gene mutation; Plasminogen activator inhibitor (PAI 1) 4G15G polymorphism; Preeclampsia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; BLOOD CLOTTING FACTOR 5; METHYLENETETRAHYDROFOLATE DEHYDROGENASE (NAD);

ADOLESCENT; ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; ONSET AGE; PREECLAMPSIA; PRIORITY JOURNAL; VEIN THROMBOSIS; GENETICS; MATERNAL AGE; MUTATION; PATHOLOGY; PREGNANCY; RISK; RISK FACTOR;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FACTOR V; FEMALE; GENOTYPE; HUMANS; MATERNAL AGE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE (NAD+); MUTATION; ODDS RATIO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRE-ECLAMPSIA; PREGNANCY; PROTHROMBIN; RISK; RISK FACTORS;

EID: 23044517241     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01226.x     Document Type: Article

References (28)

1. Myatt L, Miodovnik M. Prediction of preeclampsia. Semin Perinat 1999; 23: 45-57.
2. Walters WA, Ford BJ, Sullivan EA, King JF. Maternal death in Australia. Med J Aust 2002; 176: 413-4.
3. The National Institute for Clinical Excellence, the Scottish Executive Health Department, the Department of Health, Social Services and Public Safety, Northern Ireland. Why Mothers Die 1997-1999: The Confidential Enquiries into Maternal Deaths in the United Kingdom. London: RCOG Press, 2001.
4. Zhou Y, Damsky CH, Fisher SJ. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest 1997; 99: 2152-64.
5. Ness RB, Roberts JM. Heterogenous cases constitute the single syndrome of preeclampsia: a hypothesis and its implications. Am J Obstet Gynecol 1996; 175: 1365-70.
6. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, Mclaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989; 161: 1200-4.
7. Salafia CM, Pezzullo JC, Lopez-Zeno JA, Simmens S, Minior VK, Vintzileos AM. Placental pathologic features of preterm preeclampsia. Am J Obstet Gynecol 1995; 173: 1097-105.
8. Shanklin DR, Sibai BM. Ultrastructural aspects of preeclampsia. Placental bed and uterine boundary vessels. Am J Obstet Gynecol 1989; 161: 735-41.
9. Whigham KA, Howic PW, Drummond AH, Prentice CR. Abnormal platelet function in preeclampsia. Br J Obstet Gynaecol 1978; 85: 28-32.
10. Saleh AA, Bottoms SF, Farag AM, Dombrowski MP, Welch RA, Norman G, Mammen EF. Markers for endothelial injury, clotting and platelet activation in preeclampsia. Arch Gynecol Obstet 1992; 251: 105-10.
11. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222-31.
12. Dizon-Townson DS, Nelson LM, Easton K, Ward K. The factor V leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996; 175: 902-5.
13. Lindoff C, Ingemarsson I, Martinsson G, Segelmark M, Thysell H, Astedt B. Preeclampsia is associated with a reduced response to activated protein C. Am J Obstet Gynecol 1997; 176: 457-60.
14. Van Pampus MG, Dekker GA, Wolf H, Huijgens PC, Koopmann MM, von Blomberg BM, Buller HR. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol 1999; 180: 1146-50.
15. Kupferminc JM, Eldor A, Steinmann N, Many A, Bar-Am A, Jaffa A, Fait G, Lessing JB. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340: 9-13.
16. Schlembach D, Beinder E, Zingsem J, Wunsiedler U, Beckmann MW, Fischer T. Association of maternal and/or fetal factor V Leiden and G20210A prothrombin mutation with HELLP syndrome and intrauterine growth restriction. Clin Sci 2003; 105: 279-85.
17. De Maat MPM, Jansen Mwjc Hille ETM, Vos HL, Bloemenkamp KWM, Buitendijk S, Helmerhorst FM, Wladimiroff JW, Bertina RM, De Groot CJM. Preeclampsia and its interaction with common variants in thrombophilic genes. J Thromb Haemost 2004; 2: 1588-93.
18. Vollset SE, Refsum H, Irgens LM, Emblem BM, Tverdal A, Gjessing HK, Monsen AL, Ueland PM. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the hordaland homocysteine study. Am J Clin Nutr 2000; 71: 962-8.
19. Glueck CJ, Kupferminc MJ, Fontaine RN, Wang P, Weksler BB, Eldor A. Increased frequency of the hypofibrinolytic 4G/4G polymorphism of the plasminogen activator inhibitor-1 (PAI-1) gene in women with obstetric complications. Obstet Gynecol 2001; 97: 44-8.
20. Morrison ER, Miedzybrodzka ZH, Campbell DM, Haites NE, Wilson BJ, Watson MS, Greaves M, Vickers MA. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systemic review. Thromb Haemost 2002; 87: 779-85.
21. Hypertension in Pregnancy. Technical bulletin no. 219. Washington, DC: American College of Obstetricians and Gynecologists, January 1996.
22. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
23. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and increase in venous thrombosis. Blood 1996; 88: 3698-703.
24. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP. A candidate genetic risk factor for vascular disease in methylenetetrahydrofolate-reductase. Nat Genet 1995; 10: 111-3.
25. Nauck M, Wieland H, Marz W. Rapid, homogenous genotyping of the 4G/5G polymorphism in the promoter region of the PAI I gene by fluorescence energy transfer and probe melting curves. Clin Chem 1999; 45: 1147-7.
26. Henry M, Tregouet DA, Alessi MC, Aillaud MF, Visvikis S, Siest G, Tiret L, Juhan-Vague I. Metabolic determinants are much more important than genetic polymorphisms in determing the pai-1 activity and antigen plasma concentrations. Arterioscler Thromb Vasc Biol 1998; 18: 84-91.
27. Said J, Dekker G. Preeclampsia and thrombophilia. Best Pract Res Clin Obstet Gynecol 2003; 17: 441-58.
28. Lockwood CJ, Krikun G, Schatz F. The decidua regulates hemostasis in human endometrium. Semin Reprod Endocrinol 1999; 17: 45-51.